ERBB2 and breast carcinoma: NAC was used in 6.9 % of luminal A-type (n = 38), 10.4 % of luminal B-type (n = 26), 9.9 % of HER2 + breast cancer type (n = 11), and 17.0 % of TNBC type (n = 37).